Abstract
The susceptibility of 109 Stenotrophomonas maltophilia isolates, all characterized by pulsed-field gel electrophoresis, to nine quinolones was studied. Grepafloxacin, trovafloxacin, and moxifloxacin displayed similar intrinsic activities (MIC90, 0.5 μg/ml), which were lower than those of ofloxacin and ciprofloxacin (MIC90, 4 μg/ml), norfloxacin (MIC90, 64 μg/ml), and nalidixic acid (MIC90, 32 μg/ml). Nalidixic acid was generally one- to twofold dilutions more active than norfloxacin. According to the criteria of the National Committee for Clinical Laboratory Standards (NCCLS), the percentage of isolates susceptible to ciprofloxacin (breakpoint ≤1 μg/ml) was 76.1%. Using the NCCLS breakpoint for comparative purposes, the percentage of isolates susceptible to grepafloxacin, moxifloxacin, and trovafloxacin was 95.4, 96.4, and 96.4%, respectively. These results indicate that new quinolones may potentially be used for the management of Stenotrophomonas maltophilia infections.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Valdezate, S., Vindel, A., Baquero, F. et al. Comparative In Vitro Activity of Quinolones Against Stenotrophomonas maltophilia . EJCMID 18, 908–911 (1999). https://doi.org/10.1007/s100960050430
Issue Date:
DOI: https://doi.org/10.1007/s100960050430